Gilead: Gilead posts profit, says HIV prevention drug on track for mid-June

Gilead Sciences (GILD.O), opens new tab on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales.